Video

Comparing Two MPN Drugs

Author(s):

Trine Alma Knudsen, M.D.

An expert discusses a trial comparing recombinant interferon alpha-2 with hydroxyurea in patients with myeloproliferative neoplasms (MPNs).

Trine Alma Knudsen, M.D., a Ph.D. student in the department of hematology at the Zealand University Hospital in Roskilde, Denmark, discusses the DALIAH trial, which compared recombinant interferon alpha-2 with hydroxyurea in patients with myeloproliferative neoplasms (MPNs).

Initially, there was a higher percentage of patients in the interferon arm who stopped treatment due to toxicities. However, after about 18 months, the researchers saw that there wasn’t much difference between the two drugs. But according to other studies, Knudsen said, staying on interferon might be worth it, as it may prove to be the superior drug after a longer time on treatment.

Related Videos
Image of a woman with long red hair.
Image of a man in a suit.
Image of woman with brown hair.
Image of a man with short hair, wearing a buttoned-up shirt.
Image of a man with short black hair.
Image of a woman with tied back hair, wearing pearl earrings.
Image of a woman with layered hair, wearing a bright blue cardigan.
Image of a man with short black hair.
Image of man with gray hair.
Image of woman with black hair.
Related Content
Image of red blood cells.
October 3rd 2024

Education on MPN Symptoms, Treatments Leads to Greater Involvement in Care

Darlene Dobkowski, MA
An expert explained the importance of education and involvement in care for patients with myeloproliferative neoplasms.
Cancer Horizons podcast logo
January 8th 2024

FDA Stops Lung Cancer Trial, CAR-T Cell Therapy Is Cost Effective, Novel Drug Slows Fibrosis

Alex Biese Brielle Benyon
The year 2024 is now underway. After a busy 2023, we’re now looking back at some of the oncology headlines from the new year.
Picture of Dr. Guillermo Garcia-Manero
September 18th 2024

Why Transfusion Independence Matters for Patients With MDS

Alex Biese
An expert explained the burden that red blood cell transfusions can place on patients with MDS.
LeVar Burton Helping the MPN Community Through Advocacy and Storytelling
December 16th 2021

LeVar Burton Helping the MPN Community Through Advocacy and Storytelling

Jamie Cesanek Darlene Dobkowski, MA
On this episode of the “Cancer Horizons” podcast, LeVar Burton sits down with CURE® to talk about the importance of MPN awareness and the power of storytelling in advocacy.
doctor with blood vials
September 1st 2024

A True Partner in Cancer Healing

Wendy Stock, MD
Keri is also a true partner in the management and care of the whole patient.
Illustration of myeloproliferative neoplasms, including essential thrombocythemia.
August 31st 2024

Essential Thrombocythemia Trial Launched Evaluating Bomedemstat

Alex Biese
The Shorespan-007 trial will investigate the new drug among patients with essential thrombocythemia who have not previously received cytoreductive therapy.